Last updated on July 2019

Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)


Brief description of study

Primary Objective:

To describe the long-term safety of dupilumab in treatment of patients with moderate to severe asthma who completed the previous asthma clinical trial (TRAVERSE-LTS12551).

Detailed Study Description

Duration per participant is until dupilumab approval for use in asthma and market availability to the patient, or a maximum of 144 weeks (ie, about 3 years) after the Start of Treatment (V1), whichever comes first.

Clinical Study Identifier: NCT03620747

Find a site near you

Start Over

Investigational site nb 840057

South Burlington, VT United States
  Connect »

Belgium

Belgium, Belgium
  Connect »

CANADA

Canada, Canada
  Connect »

FRANCE

France, France
  Connect »

GERMANY

Germany, Germany
  Connect »

ISRAEL

Israel, Israel
  Connect »

Japan

Japan, Japan
  Connect »

South Africa

South Africa, South Africa
  Connect »

Netherlands

Netherlands, Netherlands
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.